Cargando…
Searching for escape-resistant anti–SARS-CoV-2 neutralizing antibodies
A major goal of SARS-CoV-2 vaccination is the induction of neutralizing antibodies (nAbs) capable of blocking infection by preventing interaction of the SARS-CoV-2 Spike protein with ACE2 on target cells. Cocktails of monoclonal nAbs can reduce the risk of severe disease if administered early in inf...
Autores principales: | Mahla, Ranjeet Singh, Dustin, Lynn B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843738/ https://www.ncbi.nlm.nih.gov/pubmed/35072657 http://dx.doi.org/10.1172/JCI157416 |
Ejemplares similares
-
Lessons from a large-scale COVID-19 vaccine trial
por: Mahla, Ranjeet Singh, et al.
Publicado: (2022) -
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
por: Cao, Yunlong, et al.
Publicado: (2021) -
Relevant of neutralizing antibody during SARS-CoV-2 infection and their therapeutic usage
por: Gupta, Sneh Lata, et al.
Publicado: (2022) -
Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations
por: Miersch, Shane, et al.
Publicado: (2021) -
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
por: Weisblum, Yiska, et al.
Publicado: (2020)